发布求助
文献互助 智能选刊 最新文献

Drug and Therapeutics Bulletin最新文献

筛选
英文 中文
Safety update: statins and myasthenia gravis. 安全更新:他汀类药物和重症肌无力。
Drug and Therapeutics Bulletin Pub Date : 2023-12-27 DOI: 10.1136/dtb.2023.000063
{"title":"Safety update: statins and myasthenia gravis.","authors":"","doi":"10.1136/dtb.2023.000063","DOIUrl":"10.1136/dtb.2023.000063","url":null,"abstract":"<p><p><b>Overview of:</b> Medicines and Healthcare products Regulatory Agency. Statins: very infrequent reports of myasthenia gravis.<i>Drug Safety Update</i> 2023;17(2):1.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138482158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SGLT2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient. 一名骨科创伤患者因服用 SGLT2 抑制剂而出现优生糖尿病酮症酸中毒。
Drug and Therapeutics Bulletin Pub Date : 2023-12-27 DOI: 10.1136/dtb.2023.250233rep
Duncan Taylor Ritchie, James Dixon
{"title":"SGLT2 inhibitor associated euglycaemic diabetic ketoacidosis in an orthopaedic trauma patient.","authors":"Duncan Taylor Ritchie, James Dixon","doi":"10.1136/dtb.2023.250233rep","DOIUrl":"10.1136/dtb.2023.250233rep","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"11-15"},"PeriodicalIF":0.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9748476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hydrocortisone for severe community acquired pneumonia in ICU. 氢化可的松治疗重症社区获得性肺炎。
Drug and Therapeutics Bulletin Pub Date : 2023-12-27 DOI: 10.1136/dtb.2023.000057
{"title":"Hydrocortisone for severe community acquired pneumonia in ICU.","authors":"","doi":"10.1136/dtb.2023.000057","DOIUrl":"10.1136/dtb.2023.000057","url":null,"abstract":"<p><p><b>Overview of:</b>Dequin PF, Meziani F, Quenot JP, et al. Hydrocortisone in severe community-acquired pneumonia. N Engl J Med 2023;388:1931-41.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50161107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MHRA issues two updates on fluoroquinolone safety MHRA 发布两份氟喹诺酮类药物安全性的最新报告
Drug and Therapeutics Bulletin Pub Date : 2023-12-11 DOI: 10.1136/dtb.2023.000069
BMJ Publishing Group Ltd
{"title":"MHRA issues two updates on fluoroquinolone safety","authors":"BMJ Publishing Group Ltd","doi":"10.1136/dtb.2023.000069","DOIUrl":"https://doi.org/10.1136/dtb.2023.000069","url":null,"abstract":"### Key learning points The Medicines and Healthcare products Regulatory Agency has issued two updates about serious safety issues associated with systemic fluoroquinolone antibiotics.1 2 In 2019, restrictions on the use of fluoroquinolone antibiotics were introduced because …","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138573028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bempedoic acid and cardiovascular outcomes. 贝哌酸与心血管结果。
Drug and Therapeutics Bulletin Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.000054
{"title":"Bempedoic acid and cardiovascular outcomes.","authors":"","doi":"10.1136/dtb.2023.000054","DOIUrl":"10.1136/dtb.2023.000054","url":null,"abstract":"<p><p><b>Overview of:</b> Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. <i>N Engl J Med</i> 2023;388:1353-64.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"180"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41194516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semaglutide: a new drug for the treatment of obesity. Semagulide：一种治疗肥胖的新药。
Drug and Therapeutics Bulletin Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.000007
Joel Lexchin, Barbara Mintzes
{"title":"Semaglutide: a new drug for the treatment of obesity.","authors":"Joel Lexchin, Barbara Mintzes","doi":"10.1136/dtb.2023.000007","DOIUrl":"10.1136/dtb.2023.000007","url":null,"abstract":"<p><p>Semaglutide (▼Ozempic solution for injection, ▼Rybelsus tablets-Novo Nordisk) was initially granted market authorisation for the treatment of type 2 diabetes as an adjunct to diet and exercise. In 2021 and 2022, regulatory agencies in the USA and Europe licensed semaglutide (▼Wegovy solution for injection-Novo Nordisk) for the treatment of individuals who are obese, or overweight and who have at least one weight-related comorbidity. Manufacturer-sponsored randomised controlled trials have shown a loss of almost 12% of body weight over a 68-week period, however, once the medication is stopped people regain most of their pretreatment weight. Gastrointestinal adverse events occur commonly with semaglutide, and pancreatitis, diabetic retinopathy and severe allergic reactions have also been reported. Extensive hype in social and general media has resulted in increased demand for semaglutide leading to supply problems across the various licensed products including those used for treatment of diabetes. In the UK, the National Institute for Health and Care Excellence has recommended semaglutide as an option for weight management for a maximum treatment duration of 2 years. Further studies are underway to assess the effect of semaglutide on longer-term health benefits.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"182-188"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50161108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Differentiation of hydrochlorothiazide-induced dermatitis from stasis dermatitis. 氢氯噻嗪性皮炎与瘀血性皮炎的鉴别。
Drug and Therapeutics Bulletin Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.249884rep
Rewan Abdelwahab, Eric G Tangalos, John Matulis
{"title":"Differentiation of hydrochlorothiazide-induced dermatitis from stasis dermatitis.","authors":"Rewan Abdelwahab, Eric G Tangalos, John Matulis","doi":"10.1136/dtb.2023.249884rep","DOIUrl":"10.1136/dtb.2023.249884rep","url":null,"abstract":"Summary A woman in her 60s with a history of hypertension and stasis dermatitis presented to a primary care clinic with a bilateral, erythematous rash on the legs, stomach","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"189-191"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9746335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A deprescribing intervention from hospital to postacute community care. 从医院到急性期后社区护理的一种描述性干预。
Drug and Therapeutics Bulletin Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.000061
{"title":"A deprescribing intervention from hospital to postacute community care.","authors":"","doi":"10.1136/dtb.2023.000061","DOIUrl":"10.1136/dtb.2023.000061","url":null,"abstract":"<p><p><b>Overview of:</b> Vasilevskis EE, Shah AS, Hollingsworth EK, et al. deprescribing medications among older adults from end of hospitalization through postacute care: a Shed-MEDS randomized clinical trial. <i>JAMA Intern Med</i> 2023;183:223-31.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"181"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66783718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changing the complexity of therapeutic monitoring. 改变治疗监测的复杂性。
Drug and Therapeutics Bulletin Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.000049
James A Cave
{"title":"Changing the complexity of therapeutic monitoring.","authors":"James A Cave","doi":"10.1136/dtb.2023.000049","DOIUrl":"10.1136/dtb.2023.000049","url":null,"abstract":"","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":"61 12","pages":"178"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138458568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety update: methotrexate and photosensitivity reactions. 安全性更新：甲氨蝶呤和光敏反应。
Drug and Therapeutics Bulletin Pub Date : 2023-11-29 DOI: 10.1136/dtb.2023.000056
{"title":"Safety update: methotrexate and photosensitivity reactions.","authors":"","doi":"10.1136/dtb.2023.000056","DOIUrl":"10.1136/dtb.2023.000056","url":null,"abstract":"<p><p><b>Overview of:</b> Medicines and Healthcare products Regulatory Agency. Methotrexate: advise patients to take precautions in the sun to avoid photosensitivity reactions. <i>Drug Safety Update</i> 2023;17:2.</p>","PeriodicalId":11277,"journal":{"name":"Drug and Therapeutics Bulletin","volume":" ","pages":"179"},"PeriodicalIF":0.0,"publicationDate":"2023-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41233269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信